subscribe
 

Webinar addresses 3D cell-based models for regenerative medicine

Presented by Dr Elad Katz, a senior scientist at AMSBIO, a new on-demand webinar explores the potential of 3D cell-based models for regenerative medicine and drug discovery.



Propofol discovery may help lead to development of new anaesthetics

New research on the most commonly used anaesthetic drug could help to unravel a long-standing mystery about how it induces a pain-free, sleep-like state.



Toolkit for nucleosome & histone research

AMSBIO has announced addition of new biotinylated histones and nucleosomes to its expanding range of recombinant nucleosomes, purified nucleosomes and full length histone proteins.



Presenting phenotypic screening strategies for chronic pain research

Cellectricon, a leading provider of advanced cell-based screening technologies and services, invites researchers to join the webinar entitled “Phenotypic Screening Strategies for Chronic Pain Research”, taking place on 5 September



Polyphor achieves first milestone in macrocycle drug discovery collaboration with Boehringer Ingelheim

Polyphor, a research-driven pharmaceutical company and leader in the discovery and development of macrocyclic drugs, has announced that Boehringer Ingelheim has decided to enter into the next stage of its drug discovery collaboration with Polyphor.



Novartis receives positive CHMP opinion for Ilaris®

Novartis receives positive CHMP opinion for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis.



Victrix CMCC chooses Cresset’s software for drug discovery consulting projects

Under a new agreement, Victrix CMCC will use Cresset’s software for their computational chemistry consulting projects.



Curie-Cancer and Sanofi cooperate in research on ovarian cancer

Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, have announced the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancer.



‘Next generation’ cancer drug shows promise in early trial

A new potential cancer drug has shown promising results in an early stage clinical trial. The drug, called AUY922, could help lead to a new way to treat a wide range of cancers including breast and lung cancer.



Cobra Biologics and Novolytics unveil successful development of bacteriophages against bacterial infection

Cobra Biologics and Novolytics have announced a breakthrough in the development of two Staphylococcus aureus based phage products for Phase I clinical trials with a 100 fold increase in upstream process yields.



Plasticell Ltd and Progenitor Labs join thriving community at SBC

Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, is pleased to welcome regenerative medicine companies Plasticell Ltd and Progenitor Labs as tenants.



Development and licensing deals speed up new drug development

Technology licensing tie-ups and more targeted discovery solutions are driving new drug developments



Pages

Subscribe

Subscribe



Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe